Presentation is loading. Please wait.

Presentation is loading. Please wait.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma by David S. Siegel, Thomas Martin,

Published byYandi Gunawan Modified over 6 years ago

Similar presentations

Presentation on theme: "A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma by David S. Siegel, Thomas Martin,"— Presentation transcript:

1 A phase 2 study of single-agent carfilzomib (PX A1) in patients with relapsed and refractory multiple myeloma by David S. Siegel, Thomas Martin, Michael Wang, Ravi Vij, Andrzej J. Jakubowiak, Sagar Lonial, Suzanne Trudel, Vishal Kukreti, Nizar Bahlis, Melissa Alsina, Asher Chanan-Khan, Francis Buadi, Frederic J. Reu, George Somlo, Jeffrey Zonder, Kevin Song, A. Keith Stewart, Edward Stadtmauer, Lori Kunkel, Sandra Wear, Alvin F. Wong, Robert Z. Orlowski, and Sundar Jagannath Blood Volume 120(14): October 4, 2012 ©2012 by American Society of Hematology

2 Survival. Survival. PFS (A) and OS (B) in response evaluable patients (n = 257) treated with single-agent carfilzomib. David S. Siegel et al. Blood 2012;120: ©2012 by American Society of Hematology

3 Responses according to demographic and baseline disease characteristics.
David S. Siegel et al. Blood 2012;120: ©2012 by American Society of Hematology

Download ppt "A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma by David S. Siegel, Thomas Martin,"

Similar presentations

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma by Paul G. Richardson,

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma by Paul G. Richardson,
Novel Therapies for Myeloma A. Keith Stewart Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Disclosure of Potential Conflicts of Interest.

Novel Therapies for Myeloma A. Keith Stewart Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Disclosure of Potential Conflicts of Interest.
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome by Annamaria Brioli, Hannah Giles,

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome by Annamaria Brioli, Hannah Giles,
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways.

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways.
Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.
by Angela Dispenzieri, A. Keith Stewart, Asher Chanan-Khan, S

by Angela Dispenzieri, A. Keith Stewart, Asher Chanan-Khan, S
Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics  Rajshekhar Chakraborty, Eli Muchtar,

Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics  Rajshekhar Chakraborty, Eli Muchtar,
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.
How I treat multiple myeloma in younger patients

How I treat multiple myeloma in younger patients
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11):3909-3918 June 1, 1997 ©1997.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma by Shaji K. Kumar, Betsy LaPlant,

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma by Shaji K. Kumar, Betsy LaPlant,
by Sandra Luna-Fineman, Kevin M. Shannon, Susan K

by Sandra Luna-Fineman, Kevin M. Shannon, Susan K
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.

Similar presentations

Ads by Google